Create your personal agenda –check the favourite icon
Overview of the rare diseases landscape and the challenges facing HTAs
Keynotes
Sheela Upadhyaya, Associate Director Highly Specialised Technologies, National Institute for Health and Care Excellence
Digital Innovation in Clinical Trial Design to support Market Access
Keynotes
Rob Scott, Chief Medical Officer, Vice President, Head Of Development, AbbVie
The Value of a Cure
Keynotes
Paul Mcloughlin, VP of Market Access & Phase IV Solutions, Covance
What is going on in Quebec about Market Access?
Keynotes
- Examining Quebec life sciences strategy: Integration of medicines and technological innovations
- Achieving cost reduction and improving access to medicines
- Re-editing the evaluation process for the introduction of innovative medication and technologies
Luc Boileau, Président-Directeur General, Inesss
Biosimilar pricing and access expectations in Europe
Keynotes
Andreia Ribeiro, Engagement Manager, Lifescience Dynamics Ltd
25 Roundtables (max 15 PAX)
Keynotes
Roundtable 10: Sustainable pricing models for orphan drugs
Roundtable 11: Accelerating access to treatments for rare diseases
Elizabeth Owen, Head Of Translational Research Development, The Muscular Dystrophy U.K.
Roundtable 12: Payer insights and engagement for Italy
Marco Marchetti, Director Of The National Center For Health Technology Assessment, Istituto Superiore di Sanita
Roundtable 13: The use of registries to assess orphan drugs
Jan Span, Member Of The Cross-Committee Task Force On Registries And Senior Clinical Assessor, Medicines Evaluation Board The Netherlands
Roundtable 14: Making sustainable healthcare work
Michael Schroter, Partner, Viopas Partners
Roundtable 15: Pricing Strategy – What to Do and When?
Andreia Ribeiro, Engagement Manager, Lifescience Dynamics Ltd
Roundtable 1: Bridging the gap between clinical development and medical affairs, tailoring clinical trials to meet both MA and HTA requirements
Roundtable 2: Developments in pricing and access for biosimilars in Europe
Cristina Martin-Rinconada, Associate Director Strategic Pricing, Biogen Biosimilars Europe
Roundtable 3: Examining emerging trends for market access in LMICs, opportunities and challenges
Roundtable 4: Capability building for RWE
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Roundtable 5: Payer engagement in the world of orphan drugs
Roundtable 5: Payer engagement in the world of orphan drugs
Fabrizio Zucca, Director Patient Access Dach, Sobi
Roundtable 6: Payer insights and engagement for BeneLux
Roundtable 7: Payer insights and engagement for Russia
Roundtable 8: Role of RWE in oncology
Roundtable 9: Exploring regulatory and market access developments in advanced therapies
Renske Ten Ham, Phd Candidate, Utrecht University
Chair’s remarks
PRICING & MARKET ACCESS
Paul Newton, Director Strategic Pricing, UCB
Chair’s remarks
RARE DISEASES
Chair’s remarks
HTA
Katja Berg, Vice President Of Operations And Payers Intelligence, Sanofi
Chair’s remarks
EMERGING MARKETS
Navin Joshi, Global Head Of Pricing, Classic And Established Products. Global Pharma, GlaxoSmithKline
Chair’s remarks
BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Can Pharma save $1 billion through the strategic use of RWE?
Evidence
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Developments in indication and combination pricing models
PRICING & MARKET ACCESS
- A look at the reimbursement and pricing environment and challenges for indication-based and combination therapy pricing
- Addressing the information gap: Infrastructure needs
- Where are we? Case studies on indication-based and combo pricing
Title TBC
RARE DISEASES
Lara Pippo, Head Of Market Access, C.S.L. Behring Spa
Comparing and Contrasting the UK and US HTA frameworks for assessing digital health
BIG DATA, DIGITAL HEALTH & ANALYTICS
Nadeem Ashraf, Medical Advisor - Diabetes, N/A
Quantifying the ‘patient voice’: the importance of tolerability and quality-of-survival in HTA decisions
HTA
- HTA and payer-relevant quantitative concepts to characterize AE profiles and tolerability will be reviewed
- HTA acceptance of these quant. approaches will be illustrated and appraised
- Examples and (potential future) approaches, for HTA and Access success will be discussed
Reg Waldeck, Market Access Strategy Leader, Bayer Corp
Emerging trends for market access in LMICs, opportunities and challenges
EMERGING MARKETS
Presentation reserved for Vistex
PRICING & MARKET ACCESS
Alejandra (Sandra) Garitonandía, Business Development, Vistex
Beyond data - Deriving Actionable Intelligence
BIG DATA, DIGITAL HEALTH & ANALYTICS
Simon Swift, Managing Director, Methods Analytics
USA perspective: Using RWE effectively to support product development
Evidence
Nneka Onwudiwe, Regulatory Reviewer, Food and Drug Administration
Do RCTS influence pricing?
PRICING & MARKET ACCESS
Mauricio Alvarez Reyes, Market Access Director, Tesaro
Going it alone: key challenges and benefits of launching a rare disease treatment in Europe
RARE DISEASES
David Boothe, Regional Commercial Head, Spark Therapeutics
The use of Ehealth tools to measure health outcomes for pricing purposes
BIG DATA, DIGITAL HEALTH & ANALYTICS
Geert Pelsmaeker, General Manager, Leaphy
Title TBC
HTA
Florian Turk, Head Of Global Payor Marketing, Sales And Relations, Sandoz
Latest HTA developments in Colombia
EMERGING MARKETS
Aurelio Mejia, Former Deputy Director Of Hta, IETS
Chair’s remarks
Evidence
Michael Lees, Head Of Value, Evidence And Portfolio Strategy, Takeda
Chair’s remarks
PRICING & MARKET ACCESS
Diane Munch, Head Of Global Pricing, Patient And Health Impact, Pfizer
Chair’s remarks
RARE DISEASES
Segolene Ayme, Founder Of Orphanet And Rare Disease Expert In Residence, ICM, Paris
Chair’s remarks
BIG DATA, DIGITAL HEALTH & ANALYTICS
Mark Duman, Nw Service Champion, Diabetes U.K.
Chair’s remarks
VALUE
Rafaat Rahmani, President, Lifescience Dynamics Ltd
Chair’s remarks
EMERGING MARKETS
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Chair’s remarks
BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Use of value frameworks within oncology in Europe
Evidence
- Innovation and launches in oncology are moving at a rapid pace, potentially resulting in a delay in formal reimbursement appraisal and guidance
- A number of value frameworks have been developed with the intent of providing rapid advice to oncologists on the clinical benefit of these new drugs
- These value frameworks have many advantages, including clarity and brevity, but they do not replace the full value assessment of a formal HTA
Gwilym Thompson, Director Worldwide Heor, BMS
Market access requirements in Germany
PRICING & MARKET ACCESS
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer Ingelheim Biopharmaceuticals Gmbh
Using payer data to support rare disease treatments in Germany
RARE DISEASES
- Reliability
- Analyses
- Outcome
Axel Boehnke, Director Market Access (Global Responsibility), MorphoSys AG
4D Insights - powering access
BIG DATA, DIGITAL HEALTH & ANALYTICS
- Aligning Payers, Policy Markers, Prescribers and Patient Insight using the power of Big Data
- Real-time Insights giving competitive advantage
- Measuring impact in real-time from within the health system
David Williams, Chief Medical Officer, Visformatics
What does value mean for payers, patients and pharma?
VALUE
Isabel Torres, Vice President Market Access, Public Affairs And Patient Advocacy For Europe And Canada, Takeda
The Sanofi Espoir Foundation- Providing new payment access systems to emerging markets
EMERGING MARKETS
Valerie Faillat, Head Of Sanofi Espoir Foundation, Sanofi
What patients expect from clinical research and researchers - and how patient advocacy can help deliver it
Evidence
Richard Stephens, Chair Of Consumer Liaison Group, National Cancer Research Institute (NCRI)
The pharmaceutical market of the Russian Federation: trends and prospects
PRICING & MARKET ACCESS
Ivan Glushkov, External Affairs Department Director, S.T.A.D.A.
Payer engagement in the world of orphan drugs
RARE DISEASES
Dennis Dionne, Chief Executive Officer, Newron Pharma
The use of big data in other industries and what pharma can learn from this
BIG DATA, DIGITAL HEALTH & ANALYTICS
Enkeleida Nikai, Head Of Real World Evidence, Senior Director At Janssen Europe, Middle East And Africa (Emea), Janssen Pharmaceutical
How to capture and quantify patient value within a commercial strategy
VALUE
Daniel Jackson, Global Head Of Market Access, Solutions And Strategy, UCB
Reimbursement and risk-sharing in South Korea
EMERGING MARKETS
Jeonghoon Ahn, Director, National Evidence-based Healthcare Collaborating Agency
Delivering affordable and sustainable medicines to patients across Europe through Biosimilars
BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Chair’s remarks
Evidence
Deven Chauhan, Senior Director, Value Evidence Leader, GlaxoSmithKline
Chair’s remarks
PRICING & MARKET ACCESS
Steven Flostrand, Senior Director Of Pricing And Market Access, Celgene
Chair’s remarks
BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
RWE – disrupter or quiet evolution?
Evidence
Sandra Leonard, Vice President Of Medical Evidence And Observational Research, AstraZeneca
Integrating care to secure early access and effective pricing
PRICING & MARKET ACCESS
Andrea Mantovani, Director Of Country Market Access, Amgen Inc
Utilising disease registries for orphan drug launch
RARE DISEASES
- Utilising disease registries is vital in rare diseases and a multicountry, multi-stakeholder approach will be discussed
- In Europe, linkage is needed as well between registries and EU Reference networks and this can prove to be an invaluable relation ship
- Technological challenges are a problem and potential approaches will be explored
Peter Rutherford, Global Medical Lead Of Orphan Renal Diseases, Vifor Pharma Group
Digital Therapeutics: The promise and the evidence
BIG DATA, DIGITAL HEALTH & ANALYTICS
Oliver Gassner, Head Digital Health Intelligence | Emea, Bayer
Increasing availability of biosimilars and examining market access policies
BIOSIMILARS
Sue Naeyaert, Global Head Government Affairs And Policy Biosimilars, Fresenius Kabi
Realising the insurance business model to establish effective partnership working
REIMBURSEMENT
Charles De Cidrac, Director Of Health Insurance, AXA
Roadmap to Reimbursement: A Review of Successes and Stumbles
REIMBURSEMENT
Evidentry standards for RWE in a changing world
Evidence
Tony Hebden, Vice President Of Health Economics And Outcomes Research, AbbVie
Insights for NICE: The evolving landscape for market access
PRICING & MARKET ACCESS
Carla Deakin, Associate Director, Office For Market Access, NICE
Innovative Value based contracting for gene therapy
RARE DISEASES
The use of real world data to generate evidence across the drug life cycle
BIG DATA, DIGITAL HEALTH & ANALYTICS
Margaret Mcdonald, Senior Director, Global Market Access, Pfizer
Market Access developments for Biosimilars in Europe
BIOSIMILARS
Philip Aubrey, Associate Director Market Access Biosimilars, Uk, Netherlands And Ireland, Biogen
Reimbursement within the world of Oncology
REIMBURSEMENT
- Oncology Environment and Patient Access to the Oncology Therapies
- Patient Access & Support Programs in Oncology
- Reimbursement issues and impact of the reimbursement delays in Oncology
Igor Rudychev, Senior Director, Business Insights, Immuno-Oncology, AstraZeneca
Create your personal agenda –check the favourite icon
Chair’s opening remarks
Keynotes
Insights for HTA harmonisation across Germany and Europe
Keynotes
Thomas Mueller, Head Of Directorate General 1 "Drugs, Medical Devices, Biotechnology", Bundesministerium fur Gesundheit
Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve access and pricing
Keynotes
- Overview of key European and global initiatives and next steps
- Looking at the role of technological innovation in access, pricing and evidence
- Working with payers, patients and pharma to generate value
Thomas Mueller, Head Of Directorate General 1 "Drugs, Medical Devices, Biotechnology", Bundesministerium fur Gesundheit
Stefan Scherer, Vice President Head Of Early Development Strategy, McKesson Specialty Health The U.S. Oncology Network
Saira Jan, Director Of Pharmacy Strategy And Clinical Integration, Blue Cross Blue Shield of New Jersey
Jaume Vidal, Policy Advisor, Eu Projects, Health Action International
Andreia Ribeiro, Engagement Manager, Lifescience Dynamics Ltd
Chair’s remarks
EVIDENCE
Gundula Schneidewind, Managing Director, Takeda Belgium
Chair’s remarks
PRICING AND MARKET ACCESS
Elizabeth Mckenna, Head Of Market Access Uk And Ireland, Vertex Pharmaceuticals
Chair’s remarks
RARE DISEASES
Josie Godfrey, Project Director, Duchenne
Chair’s remarks
AFFORDABILITY
Chair’s remarks
ADVANCED THERAPIES
Chair’s remarks
MANAGED ENTRY AGREEMENTS
Giuseppe Rosano, Member Of The Cardiovascular Working Party, European Medicines Agency
Federated & Harmonised Real World Research in the EU 2020+: A Convergence of Intent, Collaboration & Technology?
EVIDENCE
- The next decade of RWD/RWE-based research in Europe – the federated model and edge analytics
- Data harmonisation – an international initiative and the Rosetta Stone of RWD?
- What have we learned from IMI EMIF, from its original inception, project experience, and sustainability scale up
- The premise for EHDN, aims and likely impact
- Meeting the needs of multiple stakeholders
Learnings from the Netherlands in the world of pricing and market access
PRICING AND MARKET ACCESS
Jolanda Koenders, Head Of Pricing And Market Access Pharma, Novartis
Value based medicine: whose values?
RARE DISEASES
Mark Macgregor, Interim Medical Director, Acute Services, Nhs Scotland
Pharmaceutical Affordability
AFFORDABILITY
- Ability to Pay versus Willingness to Pay
- Considerations for Product-specific and Patient-specific affordability programs
- Partnering with payers/policy makers
John Alter, Vice President Pricing And Market Access, Pfizer
Developing advanced therapies for rare disease: is this sustainable?
ADVANCED THERAPIES
Diego Ardigo, Research And Development Rare Diseases Unit Head, Chiesi Farmaceutici SpA
Latest developments in managed entry agreements for Europe
MANAGED ENTRY AGREEMENTS
Katja Berg, Vice President Of Operations And Payers Intelligence, Sanofi
The role of evidence in anti-infective value assessments
EVIDENCE
Keiko Tone, Vice President Market Access, Shionogi Limited
Understanding the US healthcare model: examining oncology treatments
PRICING AND MARKET ACCESS
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna
Market access considerations for rare disease treatments
RARE DISEASES
Simon Shohet, Senior Director, Global Market Access And Pricing, Ipsen
Achieving affordability in South America
AFFORDABILITY
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
Examining the regulatory landscape for CAR-T
ADVANCED THERAPIES
- CAR T-Cell Therapy, a new therapeutic approach: Between euphoria and scepticism
- Drug or therapeutic method: first experiences in the German health care system
- Most expensive cancer treatment ever: New approaches for affordability and sustainability
Detlev Parow, Head Of Department Of Medicines, Therapeutic Appliances And Remedies, D.A.K.
Implementation of managed entry agreements over the last decade in Australia
MANAGED ENTRY AGREEMENTS
Matt Slabbert, Head Of Market Access, Advocacy And Policy, Anz, Bayer Pharmaceuticals
Chair’s remarks
PRICING AND MARKET ACCESS
David Watson, Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry
Precision medicine in oncology: challenges and possible solutions from a payer’s perspective
EVIDENCE
- What are the key challenges we face in commissioning tests and treatments in this fast-paced and innovative field?
- How can we ensure our patients have access to tests and treatments that are safe and effective despite limited evidence?
- What solutions could be considered to manage costs to payers (and our customers) and safeguard precision medicine as a sustainable option in the future?
Lucy Hoppe, Clinical Effectiveness Manager (Evidence Synthesis) In The Clinical Effectiveness Team, Bupa
Access in the new NHS landscape
PRICING AND MARKET ACCESS
Diar Fattah, Associate Director Of Medicines Optimisation, N.H.S._Dartford Gravesham and Swanley C.C.G.
Launching rare disease products to a world market
RARE DISEASES
Biosimilars and their impact on drug contracting in the value chain
CONTRACTING AND PRICE TENDERING
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Developments in CAR-T for Russia
ADVANCED THERAPIES
Daria Tolkacheva, Head Of Health Economics, JSC BIOCAD
Engaging with patients and improving outcomes
PATIENT AND PAYER ENGAGEMENT
Dawn Ireland, President, CDH International
Chair’s remarks
MEDICAL AND GOVERNMENTAL AFFAIRS
Robert Popovian, Vice President Of Government Relations, Pfizer
Pricing and reimbursement in Russia
PRICING AND MARKET ACCESS
Developing a new payment system for a polysymptomatic rare disseise
RARE DISEASES
Dennis Dionne, Chief Executive Officer, Newron Pharma
Contracting and price tendering for cancer treatments
CONTRACTING AND PRICE TENDERING
Marcela Junqueira, Head Of Strategic Affairs And Health Economics, Janssen Pharmaceutical
Using evidence to support pricing for gene therapies
ADVANCED THERAPIES
Omar Dabbous, Vice President Health Economics And Outcomes Research, AveXis Inc
Title TBC
PATIENT AND PAYER ENGAGEMENT
Dan Pettitt, Global Head Of Immunology Market Access, Johnson & Johnson
Pay for performance: discussing the first large scale study into efficacy of the model
EVIDENCE
Developments in pricing and patient access for speciality treatments
PRICING AND MARKET ACCESS
Diann Potestio, Senior Director, National Accounts, Multiple Sclerosis And Immunology, Genzyme
Accelerating access to treatments for rare diseases
RARE DISEASES
Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.
Accounting profitability and the political process: the case of R&D accounting in the pharmaceutical industry
MEDICAL AND GOVERNMENTAL AFFAIRS
Bringing gene therapies to market – strategic considerations
ADVANCED THERAPIES
Darren Walsh, Senior Director - Market Access & Govt. Affairs – EU, Orchard Therapeutics
Medical drug management a US payer perspective
MEDICAL AND GOVERNMENTAL AFFAIRS
Saira Jan, Director Of Pharmacy Strategy And Clinical Integration, Blue Cross Blue Shield of New Jersey
Advancing therapy developments through new pricing models
ADVANCED THERAPIES
Inge Bliestle, Commercial Director, Actelion
The role of RWE in HTAs and regulatory affairs in Germany
EVIDENCE
Jorg Tomeczkowski, Head Of Market Access, Janssen Cilag Germany
HTA in Switzerland
PRICING AND MARKET ACCESS
- Legal Context of HTA in Switzerland
- HTA Processes
- Implementation of HTA
Methods for clinical statistical modeling to reduce trial size
RARE DISEASES
Qing Liu, Head Of Biostatistics And Data Management, Amicus Therapeutics Inc
Landscape of Drug Pricing, Spending and Affordability In The U.S.
MEDICAL AND GOVERNMENTAL AFFAIRS
Robert Popovian, Vice President Of Government Relations, Pfizer
Developing new affordable and sustainable pricing models for a changing health landscape
ADVANCED THERAPIES
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Chair's closing remarks
MEDICAL AND GOVERNMENTAL AFFAIRS
Robert Popovian, Vice President Of Government Relations, Pfizer
last published: 13/Dec/18 16:35 GMT
Password must meet the following requirements:
- At least one letter
- At least one capital letter
- At least one number
- Be at least 6 characters
Ajan Reginald, Chief Executive Officer,
Celixir
Ajan Reginald is a co-founder and the Chief Executive Officer of Celixir, which he originally founded under the name Cell Therapy Ltd in 2009 with Nobel Laureate Professor Sir Martin Evans. Celixir is a British biotechnology company that discovers and develops life-saving and life-altering...
Hector Castro, Senior Technical Director- Pharmaceutical Economics And Financing,
Management Science For Health
More than 18 years of senior-level experience in the areas of health systems strengthening, quality assurance, strategic purchasing and provision of healthcare technologies.10 years of experience in Health Technology Assessment (HTA), health economics, health policy, priority-setting, health care...
Francis Arickx, Head Of The Directorate Reimbursement Of Medicines And Pharmaceutical Policy,
National Institute for Health and Disability Insurance RIZIV-INAMI
Francis Arickx is the secretary for the Commission for Reimbursement of Medicines at the National Institute for Health and Disability Insurance (NIHDI RIZIV/INAMI) in Belgium. In the directorate Pharmaceutical Policy within the Health Department, he manages the teams responsible for administrative ...
Vitaly Omelyanovskiy, General Director, Center Of Healthcare Quality Assessment And Control,
Ministry of Health
In 1987 he graduated from Pirogov Russian National Research Medical University with a specialization in “General Medicine”. In 1998 he graduated from the Russian Presidential Academy of National Economy and Public Administration with a specialization in “State and Municipal Management”. In 1991 he...
Patrick Mollon, Former Director Gheore,
Shire
Patrick Mollon, MD, ESSEC MBA, MSc acquired his medical qualification in Lyon’sSchool of Medicine, France where he also gained a Masters Degree in Medical andBiological Sciences, including Pharmacology, Psychology and Medical Statistics. Priorto this, he received an MBA from the Superior School of...
Patrick Hopkinson, Executive Director, Wwheor Markets,
Bristol-Myers Squibb
Patrick is Executive Director World Wide Health Economics and Outcomes Research (WWHEOR) Markets at Bristol Myers Squibb. He leads the team responsible for supporting country HTA submissions and access. He is responsible for all countries outside of the US. Patrick also leads WWHEOR HTA Policy...
Wills Hughes-Wilson, Head Of Patient Access And Commercial Planning,
Mereo BioPharma
Wills Hughes-Wilson is Head of Patient Access & Commercial Planning at Mereo Biopharma and a member of the company’s executive leadership team. She joined Mereo in February 2018 with responsibility for leading and optimising the company’s patient access and commercialisation strategies. Prior...
Marco Rauland, Vice President, Map GmAndE And Training Academy, Global Market Access And Pricing, Biopharma| Global Operations,
Merck Group
Marco Rauland has more than 20 years of drug development, marketing, market research and pricing consulting experience in the pharmaceutical industry. Prior to joining Merck Marco was Vice President Europe of GfK's Market Access practice. Before that Marco was the global head of the...
Hector Castro, Senior Technical Director- Pharmaceutical Economics And Financing,
Management Science For Health
More than 18 years of senior-level experience in the areas of health systems strengthening, quality assurance, strategic purchasing and provision of healthcare technologies.10 years of experience in Health Technology Assessment (HTA), health economics, health policy, priority-setting, health care...
Alison Kneen, Practice Lead,
DRG Abacus
Alison Kneen is a Practice Lead at DRG Abacus. She has a passion for market access and public affairs and is seen as a global expert in all aspects of market access and reimbursement strategies. She brings extensive international experience built over 34 years in the pharmaceutical industry, with...
Kevin Mayo, Head, Global Market Access - New Products,
Shire Pharmaceuticals
Dr. Kevin Walker Mayo is Global Head, Market Access New Products for PTC Therapeutics where he is supporting their gene therapy, alternative splicing, nucleotide repeat, protein modification, transcript regulators and nonsense readthrough scientific platforms for discovering rare disease...
Martina Flammer, Senior Vice President, Head Of Customer Value,
Boehringer Ingelheim Pharma GmbH & Co. KG
Martina operates at the forefront of functional developments in Market Access, Pricing & HEOR, Epidemiology and Real World Evidence (RWE) to advance state-of-the-art standards and ensure they are consistently applied and met throughout the organization from drug development, via product...
Daniel Knecht, Vice President, Clinical Strategy And Policy,
Aetna
A board-certified internist and a Fulbright scholar, Dr. Knecht has developed insights into the health care industry through experiences in pharmaceutical entrepreneurship, life science strategy consulting, patient care and population health research. Dr. Knecht currently serves as Vice President...
Stephen Deitch, Vice President,
Charles River Associates
Stephen Deitch is a vice president in the Life Sciences Practice at CRA. He has 30 years of experience in a variety of senior health care and life science positions as a consultant, payer, and pharmacist. Stephen has led engagements on a broad variety of commercial issues. He has worked across a...
Dr Josep Torrent-Farnell, Medicines Department,
Catalan Health Service
Dr. Josep Torrent-Farnell. PhD in Medicine and Surgery and Bachelor of Pharmacy, specialist in internal medicine and clinical pharmacology. Head of the medicine division of the CatSalut, of the Generalitat de Catalunya (May 2016). Full Professor of the Department of Clinical and Therapeutic...
Nigel Hughes, Scientific Director,
Janssen
Scientific Director, RMEDS Quantitative Sciences, Janssen Pharm R&D. A former UK NHS healthcare & voluntary sector professional working in the pharmaceutical and diagnostics industry with a 360° experience in the blood borne virus market based on a professional heritage in the viral...
Eva Marchese, Vice President,
CRA International
![Eva Marchese, Vice President, CRA International]()
Eva Marchese specializes in competitive strategy, pricing, market access, and research primarily in the pharmaceutical, biotech, and life sciences industries. She has an extensive consulting background with a focus on advising pharmaceutical and medical device companies on global pricing and market ...
Ajan Reginald, Chief Executive Officer,
Celixir
Ajan Reginald is a co-founder and the Chief Executive Officer of Celixir, which he originally founded under the name Cell Therapy Ltd in 2009 with Nobel Laureate Professor Sir Martin Evans. Celixir is a British biotechnology company that discovers and develops life-saving and life-altering...
Maurício Silva De Lima, Vice President, Us Medical Affairs Head, Spectrum Medical Unit,
Genentech
Mauricio is a VP and Head of Spectrum, US Medical Affairs. He holds a Medical Degree from Federal University of Pelotas, Brazil, where he also did his psychiatric training. After many years of clinical practice as a psychiatrist and teaching in Medical Schools, he started his research training in...
Vitaly Omelyanovskiy, General Director, Center Of Healthcare Quality Assessment And Control,
Ministry of Health
In 1987 he graduated from Pirogov Russian National Research Medical University with a specialization in “General Medicine”. In 1998 he graduated from the Russian Presidential Academy of National Economy and Public Administration with a specialization in “State and Municipal Management”. In 1991 he...
Lotte Steuten, Associate Faculty Member,
Fred Hutchinson Cancer Research Center
Dr. Lotte Steuten is an entrepreneurial academic, striving to accelerate patient access to high-value healthcare innovations. She has deep expertise in health economics and evidence development that she applies to identifying and articulating the clinical, humanistic and economic value of medical...
Joerg Mahlich, Head Heor,
Janssen Pharmaceutical K.K.
Jörg Mahlich graduated in economics from the University of Kiel/Germany and holds a doctoral degree in economics from the University of Vienna/Austria. He is currently heading the health economics department at Janssen Japan in Tokyo. Previous to that he was in the market access team of Janssen...
Goedele Van Haasteren, Hta Specialist,
Bundesamt fur Gesundheit
Health Technology Assessment (HTA) specialist with profound experience in technology assessment, development of evidence-based practice guidelines and teaching materials, clinical research, consulting related to health technologies, and academic teaching.
